Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Docetaxel, Androgen Ablation, and Radiotherapy for High-Risk Prostate Cancer
NCT00225420Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2005
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 2 years. Started Aug 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00225420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225420.